biotech / news / / Seeking Alpha
Lilly to acquire cancer drug developer Kelonia for up to $7B.
Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion in cash.
KEY POINTS
- Kelonia Therapeutics is a privately held company focused on developing cancer drugs.
- The acquisition confirms earlier reporting by The Wall Street Journal.
- This move signals Lilly's further expansion into cancer drug development.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →